Helen Paguntalan
Irvine, CANPI 1659663045
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $730 of the $1,109 with a category attached, or 65.8%. Kedrion Biopharma Inc. accounts for 65.8% of it on its own, with 1 other manufacturer making up the rest.
Across 10 payments — averaging $110.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kedrion Biopharma Inc.$730
- Abbott$379
Across 11 payments — averaging $319,292 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$3.2M
- E.r. Squibb & Sons, L.L.C.$256K
- Sanofi Pasteur Inc.$21K
- Teva Pharmaceuticals USA, Inc.$3K
What the payments were for
- Speaking & faculty fees$73066%
- Travel & lodging$25123%
- Food & beverage$12812%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kedrion Biopharma Inc. | 1 | $730 |
| Abbott | 9 | $379 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEDRAB$730
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.